MapLight director buys 25,000 MPLT shares

MapLight Therapeutics director George Pavlov bought 25,000 shares of Voting Common Stock in open-market transactions.

Rhea-AI Filing Summary

MapLight Therapeutics director George Pavlov bought 25,000 shares of Voting Common Stock in open-market transactions. The purchases occurred on February 18, 19, and 20, 2026, at weighted average prices of about $17.48, $17.57, and $17.86 per share, bringing his directly held stake to 25,000 shares.

Insider Trade Summary

Net Buyer: 25,000 shares

Net Buy 3 txns

Insider Pavlov George

Role Director

Bought 25,000 shs ($441K)

Type	Security	Shares	Price	Value
Purchase	Voting Common Stock	9,920	$17.86	$177K
Purchase	Voting Common Stock	4,422	$17.57	$78K
Purchase	Voting Common Stock	10,658	$17.48	$186K

Holdings After Transaction: Voting Common Stock — 25,000 shares (Direct)

Footnotes (3)

1. F1. The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.22 to $17.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
2. F2. The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.28 to $17.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
3. F3. The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.74 to $17.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did MapLight Therapeutics (MPLT) director George Pavlov report on this Form 4?

George Pavlov reported open-market purchases of MapLight Therapeutics Voting Common Stock. Over three days in February 2026, he bought a total of 25,000 shares, increasing his directly held ownership to 25,000 shares after the reported transactions.

How many MapLight Therapeutics (MPLT) shares did George Pavlov buy and on which dates?

George Pavlov bought 25,000 shares of Voting Common Stock in total. He purchased 10,658 shares on February 18, 4,422 shares on February 19, and 9,920 shares on February 20, 2026, in separate open-market transactions.

At what prices did George Pavlov purchase MPLT stock according to the Form 4?

The Form 4 lists weighted average prices for each day’s trades: about $17.48 per share on February 18, $17.57 on February 19, and $17.86 on February 20, 2026. Actual individual trade prices fell within specified ranges in the footnotes.

What is George Pavlov’s MapLight Therapeutics (MPLT) share ownership after these transactions?

After the reported purchases, George Pavlov directly owns 25,000 shares of MapLight Therapeutics Voting Common Stock. Each transaction’s table entry shows the total shares following the transaction, culminating in 25,000 shares held directly as of the final reported trade.

What do the footnotes in George Pavlov’s MPLT Form 4 filing explain about the purchase prices?

The footnotes state that each reported price is a weighted average. Shares on each day were bought in multiple trades within specific price ranges, and Pavlov undertakes to provide detailed trade-by-trade pricing information to the issuer, security holders, or SEC staff upon request.

Were George Pavlov’s MPLT share purchases direct or through another entity?

The Form 4 characterizes these holdings as direct ownership. Each transaction is coded with ownership type and code as “D,” indicating the Voting Common Stock shares acquired in these open-market purchases are held directly rather than through an intermediate entity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/20/2026 - 06:25 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pavlov George

(Last) (First) (Middle)

C/O MAPLIGHT THERAPEUTICS, INC.

800 CHESAPEAKE DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MapLight Therapeutics, Inc. [ MPLT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Voting Common Stock	02/18/2026		P		10,658	A	$17.48(1)	10,658	D
Voting Common Stock	02/19/2026		P		4,422	A	$17.57(2)	15,080	D
Voting Common Stock	02/20/2026		P		9,920	A	$17.86(3)	25,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.22 to $17.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

2. The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.28 to $17.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

3. The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.74 to $17.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

	/s/ Kristopher L. Hanson, Attorney-in-Fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.